Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River’s immunology expertise to refine study ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Patients receiving an immune checkpoint inhibitor for a neoplasm face an increased risk for rheumatoid arthritis, an observational study found.

Conduit Pharmaceuticals (CDT) announces an agreement with Charles River Laboratories (CRL) to evaluate AZD1656 in a clinically relevant ...

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles River Laboratories to help test the asset in a preclinical model of the ...

Selena Gomez has been in the spotlight thanks to her Golden Globe nomination for Emilia Pérez and her engagement to musician ...

Cullinan Oncology LLC (CGEM) stock has reached a new 52-week low, trading at $9.48 USD, signaling a period of significant ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial results for ...

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company” or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...